Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better?
|
|
- Jonathan Brendan Crawford
- 5 years ago
- Views:
Transcription
1
2 Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? 9 th European Kidney Cancer Symposium, Dublin, April 2014 Tim Eisen
3 Tim Eisen - Disclosures Company Research Support Advisory Board Trial Management Group Honoraria Astra Zeneca Astellas + + Aveo Bayer GSK Immatics + Pfizer Roche + +
4 Appraisal
5 40 Years of Developing mrcc Treatments Cytokines IL-2 and IFN-α High-dose IL-2 FDA approval based on phase II data Pazopanib Everolimus Bevacizumab+IFN-α Temsirolimus Sorafenib Sunitinib Axitinib VHL tumour suppressor gene isolated Chromatin Remodelling Gene Mutations
6 Failed studies a BIG issue 935 / 7776 Phase II / III studies did not complete Accrual 38.7% Sponsor decision 10.7% Interim analysis 9.9% Toxicity 8.2% Funding 5.6% Stensland et al., GU ASCO 2014
7 Nephrectomy in mrcc: Key Questions in the TKI Era Is cytoreductive nephrectomy benefical? If so, should nephrectomy or TKI come first?
8 CARMENA V SURTIME
9 There are many ongoing Phase III studies of adjuvant targeted therapy in RCC... Trial Treatment arms and duration Patients N SORCE 1 Sorafenib (3 years) Sorafenib (1 year) then placebo (2 years) Placebo (3 years) Resected clear-cell/non-clear-cell RCC and intermediate- or high-risk disease 1656 ASSURE 2 Sorafenib Sunitinib Placebo 1 year Resected clear-cell/non-clear-cell RCC and intermediate-high- or very-high-risk disease 1923 S-TRAC 3 Sunitinib Placebo 1 year Resected predominantly clear-cell RCC and high-risk disease 720 PROTECT 4 Pazopanib Placebo 1 year Resected (predominantly) clear-cell RCC with high or moderately high risk of recurrence 1500 EVEREST 5 Everolimus Placebo 54 weeks Resected clear-cell/non-clear-cell RCC and intermediate-high- or very-high-risk disease NCT ; 2. NCT ; 3. NCT ; 4. NCT ; 5. NCT
10 Adjuvant studies in RCC: Divided we fall? Placebo / control 3143 Sorafenib 1yr (SORCE)1242 Pazopanib (PROTECT) 750 Sorafenib (ASSURE) 641 Sunitinib (ASSURE) 641 Everolimus (EVEREST) 609 Sunitinib (S-TRAC) 300
11 ARISER (G250 v Placebo) Metastases at baseline in 11% Median DFS 71 months 5 year OS 78% Risk Group Staging % of total Leibovich Score 1 T3/4; N0/X; M0 75% Any T; N+; M0 8% T1b/2; N0/NX; M0; G>3 17% 3-8 Belldegrun et al., ASCO 2013
12 MAMS vs traditional Traditional Approach Multi-arm, Multi-stage Phase II T1 T2 T3 T4 C T1 T2 T3 T4 Phase II Phase III C T1 C T3 C T4 Phase III
13 Predictors of Successful Phase III Trials Strong Phase II signal / scientific rationale Predictive marker Robust outcome magnitude and relevance Efficient and effective design Clin Cancer Res Dec 15;16(24): doi: / CCR Translating clinical trials into meaningful outcomes. LoRusso PM 1, Schnipper LE, Stewart DJ, Boerner SA, Averbuch SD, Wolf W.
14 Recent Negative Trials in mrcc Study Setting Experimental Arm Standard Arm INTORSECT 2 nd line Temsirolimus Sorafenib INTORACT 1 st line Bev/Tem Bev/IFN RECORD 2 1 st line Bev/Evero Bev/IFN GOLD 3 rd line Dovitinib Sorafenib AGILE 1 st line Axitinib Sorafenib TIVO 1 1 st line Tivozanib Sorafenib Comment
15 INTORSECT Phase III Study Design 1 Key eligibility criteria: mrcc PD on 1st-line sunitinib Stratification factors: Duration of sunitinib therapy ( or > 6 mos) MSKCC risk group Histology (clear cell or non clear-cell) Nephrectomy status R A N D O M I Z A T I O N 1:1 N = 512 Temsirolimus 25 mg IV weekly a n = 259 Sorafenib 400 mg oral BID a n = 253 Primary end point: PFS (IRC) Secondary end points: OS, PFS (investigator), PFS at 12, 24, and 36 weeks, ORR, duration of response a Dose reductions were allowed: temsirolimus (to 20 mg then 15 mg); sorafenib (to 400 mg/day, then every other day) 1. Hutson TE et al ESMO 2012; abstract LBA22_PR
16 Prospective Data: INTORSECT Phase III Study Efficacy 1 No significant difference in PFS between temsirolimus and sorafenib OS significantly longer with sorafenib (P=0.014) Median PFS, 1.0 months 95% CI Temsirolimus Sorafenib , , P= (log-rank) Stratified HR: 0.87 (95% CI: 0.71, 1.07) Patients at risk, n Time (months) Sorafenib Temsirolimus PFS (probability) Progression-Free Survival (IRC Assessment) Median OS, 1.0 months 95% CI Temsirolimus Sorafenib , , P=0.014 (log-rank) Stratified HR: 1.31 (95% CI: 1.05, 1.63) Patients at risk, n Time (months) Sorafenib Temsirolimus Overall Survival (probability) Overall Survival CI, confidence interval; HR, hazard ratio; IRC, Independent Review Committee; OS, overall survival; PFS, progression-free survival 1. Hutson TE et al ESMO 2012; abstract LBA22_PR
17 Prospective Data: INTORSECT Phase III Study Efficacy 1 No significant difference in PFS between temsirolimus and sorafenib OS significantly longer with sorafenib (P=0.014) Median PFS, 1.0 months 95% CI Temsirolimus Sorafenib , , P= (log-rank) Stratified HR: 0.87 (95% CI: 0.71, 1.07) Patients at risk, n Time (months) Sorafenib Temsirolimus PFS (probability) Progression-Free Survival (IRC Assessment) Median OS, 1.0 months 95% CI Temsirolimus Sorafenib , , P=0.014 (log-rank) Stratified HR: 1.31 (95% CI: 1.05, 1.63) Patients at risk, n Time (months) Sorafenib Temsirolimus Overall Survival (probability) Overall Survival CI, confidence interval; HR, hazard ratio; IRC, Independent Review Committee; OS, overall survival; PFS, progression-free survival 1. Hutson TE et al ESMO 2012; abstract LBA22_PR
18 Recent Negative Trials in mrcc Study Important question? Strong rationale? Predictive marker? INTORSECT Yes Yes No Yes INTORACT RECORD 2 GOLD AGILE TIVO 1 Good design?
19 Rationale for Bevacizumab / Temsirolimus combination Phase I study: N = 12, all ECOG 0-1 Prior therapy: n = 7, cytokines in 6/7 RR: NO CR PR=7 (60 %) SD = 3 (25 %) PFS: n/a Combination feasible with both agents given at full dose High response rate further testing recommended Merchan ASCO
20 Rationale for Everolimus/Bevacizumab combination Phase II study: N = 30 untreated patients in preliminary report N = 50 untreated patients in final report Median PFS: 12 months in ASCO 2008 presentation (9 months in abstract) 9.1 months in the final report (JCO 2010) RR: NO CR PR=23 % SD = 53 % Combination feasible with both agents given at full dose Very active ( 12 months PFS ) further testing recommended Whorf et al ASCO 2008; Hainsworth et al JCO
21 Recent Negative Trials in mrcc Study Setting Experimental Arm Standard Arm Comment INTORSECT 2 nd line Temsirolimus Sorafenib Positive INTORACT 1 st line Bev/Tem Bev/IFN Ph I signal RECORD 2 Large Ph II 1 st line Bev/Evero Bev/IFN Ph II signal +/- GOLD 3 rd line Dovitinib Sorafenib True negative AGILE 1 st line Axitinib Sorafenib TIVO 1 1 st line Tivozanib Sorafenib
22 AGILE Study Design* Previously untreated metastatic RCC R A N D O M I Z E 2:1 Axitinib 5 mg BID (n=192) Sorafenib 400 mg BID (n=96) Primary endpoint: PFS Randomization stratified by ECOG PS (0 vs 1). * ClinicalTrials.gov: NCT Titrated stepwise to 7 mg BID and then 10 mg BID in patients without grade 3 or 4 (CTCAE v3.0) axitinib-related AEs for a consecutive 2-week period, unless BP >150/90 mmhg. 22
23 PFS (probability) Progression-free Survival (IRC Assessment) No. events (%) 1.0 Axitinib 111 (58) 0.9 Sorafenib 60 (63) sided P= = censored for axitinib 0.1 = censored for sorafenib Time (months) Stratified HR, 0.77* (95% CI ) mpfs, mo (95%CI) 10.1 ( ) 6.5 ( ) * Stratified by ECOG PS; assuming proportional hazards, HR <1 indicates a reduction in favor of axitinib and HR >1 indicates a reduction in favor of sorafenib. IRC = independent radiology committee; mpfs = median progression-free survival Patients at risk, n Axitinib Sorafenib
24 Statistical Design Primary endpoint for first-line comparison was PFS, assessed by independent radiology committee (IRC) 90% power to detect a 78% improvement in mpfs from 5.5 mo with sorafenib to 9.8 mo with axitinib, corresponding to an HR of 0.56 (overall 1-sided α=0.025) An estimated 247 treatment-naïve patients were needed to observe the required 148 IRC-assessed PFS events One interim futility analysis was planned at 74 (50%) investigator-assessed PFS events; independent data monitoring committee (DMC) could adjust number of IRC-assessed PFS events based on conditional power at interim analysis Number of PFS events was increased to 169 by DMC 24
25 Recent Negative Trials in mrcc Study Setting Experimental Arm Standard Arm Comment INTORSECT 2 nd line Temsirolimus Sorafenib True negative INTORACT 1 st line Bev/Tem Bev/IFN Ph I signal RECORD 2 Large Ph II 1 st line Bev/Evero Bev/IFN Ph II signal +/- GOLD 3 rd line Dovitinib Sorafenib True negative AGILE 1 st line Axitinib Sorafenib Statistics TIVO 1 1 st line Tivozanib Sorafenib
26 TIVO-1: Phase III superiority study of tivozanib vs sorafenib as first-line targeted therapy for advanced RCC Key eligibility criteria Advanced RCC Clear cell histology Measurable disease Prior nephrectomy 0 1 prior therapy for mrcc No prior VEGF or mtor therapy ECOG PS 0 1 Stratification factors Geographic region Prior treatments for mrcc Number of metastatic lesions R A N D O M I S E D 1:1 Tivozanib 1.5 mg/day p.o., 3 weeks on/1 week off (N=260) Sorafenib 400 mg p.o. b.d., continuous (N=257) Progression Crossover to tivozanib via separate protocol Motzer et al. J Clin Oncol 2012; 30(Suppl): Abstract 4501 (Oral presentation) 26
27 Tivozanib is superior to sorafenib for PFS (primary endpoint, independent radiological review) Probability of PFS (%) Median PFS, months (95% CI) Tivozanib 11.9 ( ) Sorafenib 9.1 ( ) HR=0.797; P=0.042 Tivozanib Sorafenib Time since randomisation (months) 20 No. at risk Tivozanib Sorafenib ITT population Data on file, AVEO/Astellas Pharma 2012, Study 301 CSR, Table 17 and Figure 3 Motzer et al. J Clin Oncol 2012; 30(Suppl): Abstract 4501 (Oral presentation) 27
28 Use of next-line treatments confounds the OS comparison Randomised to tivozanib arm (n=260) Still on tivozanib treatment 27% (n=71) Discontinued initial therapy 73% (n=189) 64% 18% 10% 8% VEGF (n=18) mtor (n=16) No therapy (n=121) Other*(n=34) Randomised to sorafenib arm (n=257) Still on sorafenib treatment 12% (n=31) * Other includes radiotherapy and cytokines Due to rounding, total does not equal 100% Discontinued initial therapy 88% (n=226) 3% 2% 26% 70% (156/158 patients received tivozanib) VEGF (n=158) mtor (n=4) No therapy (n=58) Other * (n=6) Motzer et al. J Clin Oncol 2013; 31(Suppl 6): Abstract 350 (Poster) 28 28
29 TIVO-1: final OS analysis Tivozanib Sorafenib (includes patients who crossed over) Median OS, months (95% CI) 28.8 (22.5 NR) 29.3 (29.3 NR) Survival (%) Tivozanib arm Sorafenib arm a HR=1.25; P= Time (months) No. at risk Tivozanib Sorafenib a includes patients who crossed over to tivozanib after progression on sorafenib Motzer et al. J Clin Oncol 2013; 31(Suppl 6): Abstract 350 (Poster) 29 29
30 Recent Negative Trials in mrcc Study Setting Experimental Arm Standard Arm Comment INTORSECT 2 nd line Temsirolimus Sorafenib Positive INTORACT 1 st line Bev/Tem Bev/IFN Ph I signal RECORD 2 Large Ph II 1 st line Bev/Evero Bev/IFN Ph II signal +/- GOLD 3 rd line Dovitinib Sorafenib True negative AGILE 1 st line Axitinib Sorafenib Statistics TIVO 1 1 st line Tivozanib Sorafenib Design
31 Conclusions Perspective Help ourselves in difficult situations Minimise Risk & Maximise Efficiency: How persuasive will the data be? Try to foresee consequences of design Strength of Phase II / scientific rationale Realistic statistical design Novel designs Phase II: Use RECIST as a continuous variable Multi-Arm Multi-Stage
32
Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors?
Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors? Bernard Escudier Institut Gustave Roussy Villejuif, France EIKCS Lyon April 2015 What is the current role of mtor inhibitors?
More informationWill All Adjuvant Therapy Trials Be Negative in RCC?
Will All Adjuvant Therapy Trials Be Negative in RCC? Tim Eisen Eleventh European International Kidney Cancer Symposium 29-30 April 2016 Crowne Plaza Barcelona Fira Center, Barcelona, Spain Tim Eisen -
More informationEvidenze cliniche nel trattamento del RCC
Criteri di scelta nel trattamento sistemico del carcinoma renale Evidenze cliniche nel trattamento del RCC Alessandro Morabito Unità Sperimentazioni Cliniche Istituto Nazionale Tumori di Napoli Napoli,
More informationNew strategies and future of target therapy in advanced kidney cancer
New strategies and future of target therapy in advanced kidney cancer VHL Gene Inactivation VHL Complex Disrupted VHL Protein HIF1-a, HIF2-a Accumulation VEGF PDGF TGF-α, CXCR4 Angiogenesis Endothelial
More informationLinee guida terapeutiche oncologiche. Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona
Linee guida terapeutiche oncologiche Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona 1 YOUNG SPECIALIST RENAL CARE Verona, 07-08 Marzo 2014 Clinical
More informationTiming of targeted therapy in patients with low volume mrcc. Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital
1 Timing of targeted therapy in patients with low volume mrcc Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital 2 Wont be discussing: Symptomatic patients High volume disease Rapidly growing metastases
More informationSequencing of therapies in mrcc. Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC
Sequencing of therapies in mrcc Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC Old Paradigm Sequencing approved agents VEGF TKI Sunitinib Pazopanib Axitinib TKI TKI MTORi
More informationWhat can we expect from running phase III trials: will all of them alter the current treatment algorithm?
What can we expect from running phase III trials: will all of them alter the current treatment algorithm? 8 th European International Kidney Cancer Symposium Budapest, May 2013 Martin Gore PhD FRCP Royal
More informationTreatment Algorithm and Therapy Management in mrcc. Manuela Schmidinger Medical University of Vienna Austria
Treatment Algorithm and Therapy Management in mrcc Manuela Schmidinger Medical University of Vienna Austria A Paradigm Shift in the Treatment of mrcc 1. Sunitinib 2. Sorafenib 3. Bevacizumab+IFN-alpha
More informationDavid N. Robinson, MD
David N. Robinson, MD Background and Treatment of mrcc Background ~ 64,770 new cases of kidney/renal pelvis cancers will be diagnosed in the US in 2012 with an estimated 13,570 deaths [1] ~ 75% are clear-cell
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationDevelopping the next generation of studies in RCC
Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,
More informationRenal Cell Carcinoma: Status of Medical and Surgical Therapy. Ronald M. Bukowski Emeritus Physician Cleveland Clinic Foundation
Renal Cell Carcinoma: Status of Medical and Surgical Therapy Ronald M. Bukowski Emeritus Physician Cleveland Clinic Foundation Metastatic Renal Cell Carcinoma: Evolution of Current Therapeutic Approaches
More informationTratamiento adyuvante y neoadyuvante del cáncer renal en Xavier Garcia del Muro Solans Institut Català d Oncologia Hospitalet.
Tratamiento adyuvante y neoadyuvante del cáncer renal en 2017 Xavier Garcia del Muro Solans Institut Català d Oncologia Hospitalet. Barcelona Pronóstico del CR mediante un sistema integrado en 468 pts
More informationASCO 2011 Genitourinary Cancer
ASCO 2011 Genitourinary Cancer Expanding Options for Chronic Diseases? Walter Stadler, MD, FACP University of Chicago Disclosures (All Non-University &/or Financial Dealings with Potential, Real, or Perceived
More informationI Kid(ney) You Not: Updates on Renal Cell Carcinoma
Disclosures I Kid(ney) You Not: Updates on Renal Cell Carcinoma Nothing to disclose Renee McAlister, PharmD, BCOP Clinical Pharmacist, GU/Melanoma Vanderbilt Ingram Cancer Center September 29, 2018 Objectives
More informationInmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea
Inmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea Daniel Castellano Oncología Médica. Unidad de Tumores Genito-Urinarios Hospital Universitario 12 de Octubre I + 12
More informationPrognostic Factors for mrcc: Relevance in Clinical Practice
Prognostic Factors for mrcc: Relevance in Clinical Practice Daniel Heng MD MPH FRCPC Chair, GU Tumor Group Tom Baker Cancer Center University of Calgary Prognostic Factors Patient Factors Performance Status
More informationInnovaciones en el tratamiento del ca ncer renal. Enrique Grande
Innovaciones en el tratamiento del ca ncer renal Enrique Grande The enriched inflammatory environment of RCC Chen Z, et al. Nat Rev Cancer 2014 Available agents are expanding across the three eras of arcc
More informationTargeted Therapy in Advanced Renal Cell Carcinoma
Targeted Therapy in Advanced Renal Cell Carcinoma Brian I. Rini, M.D. Department of Solid Tumor Oncology Glickman Urologic and Kidney Institute Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio
More informationSecond - Line Debate: Axitinib
Second - Line Debate: Axitinib Alain Ravaud, MD PhD Bordeaux, France DISCLOSURES Member of Global, European and/or French advisory board in RCC and/or GU tumors for Pfizer, Novartis, GSK, Roche, BMS, Merck.
More informationMetastatic Renal Cancer Medical Treatment
Metastatic Renal Cancer Medical Treatment Bohuslav Melichar, M.D., Ph.D. Professor and Head Department of Oncology Palacký University Medical School and Teaching Hospital Olomouc, Czech Republic Peculiarities
More informationFifteenth International Kidney Cancer Symposium
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationCLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY FOR THE RIGHT PATIENT
Daniel Heng, MD, MPH, FRCPC @DrDanielHeng Chair GU Tumour Group, Tom Baker Cancer Centre Clinical Professor, University of Calgary CLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY
More informationThe Therapeutic Landscape in Advanced Renal Cell Carcinoma
The Therapeutic Landscape in Advanced Renal Cell Carcinoma Cora Sternberg, MD, FACP Chairman, Department of Medical Oncology San Camillo-Forlanini Hospital Rome, Italy What best describes the change in
More informationCytoreductive Nephrectomy
Cytoreductive Nephrectomy Stephen H. Culp, M.D., Ph.D. Assistant Professor, Department of Urology Outline The Historics of CN The current status of CN The importance of patient selection Cytoreductive
More informationpan-canadian Oncology Drug Review Stakeholder Feedback on a pcodr Request for Advice Axitinib (Inlyta) for Metastatic Renal Cell Carcinoma
pan-canadian Oncology Drug Review Stakeholder Feedback on a pcodr Request for Advice Axitinib (Inlyta) for Metastatic Renal Cell Carcinoma Pfizer Canada Inc. June 29, 2017 3 Stakeholder Feedback on a pcodr
More informationImmunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?
Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE
More informationA randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care
A randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care Martin H. Voss 1, Thomas Hutson 2, Arif Hussain 3, Ulka
More informationSergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy
Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Ninth European International Kidney Cancer Symposium Dublin 25-26
More informationImmunotherapy for Renal Cell Carcinoma. James Larkin
Immunotherapy for Renal Cell Carcinoma James Larkin Disclosures Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): Eisai, BMS, MSD, GSK, Pfizer, Novartis, Roche/Genentech
More informationEmerging Biomarkers of VEGF and mtor Inhibitors in 2015
Emerging Biomarkers of VEGF and mtor Inhibitors in 2015 Laurence Albiges Institut Gustave Roussy, France Fourteenth International Kidney Cancer Symposium Miami, Florida, USA November 6-7, 2015 www.kidneycancersymposium.com
More informationMultidisciplinary approach for renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute
Multidisciplinary approach for renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute 20 April, Antalya, Turkey RCC European Union 60.000 new diagnoses/year 26.000 Cancer related deaths
More informationUPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA. Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA
UPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA DISCLAIMER Please note: The views expressed within this presentation
More informationMedical Management of Renal Cell Carcinoma
Medical Management of Renal Cell Carcinoma Lin Mei, MD Hematology-Oncology Fellow Hematology, Oncology and Palliative Care Virginia Commonwealth University Educational Objectives Background of RCC (epidemiology,
More informationWinship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients
Winship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients Bradley Carthon, MD, PhD Assistant Professor, Genitourinary Medical Oncology Winship
More informationA Review in the Treatment Options for Renal Cell Cancer
A Review in the Treatment Options for Renal Cell Cancer Ali McBride, PharmD, MS BCPS, BCOP Clinical Coordinator Hematology/Oncology Department of Pharmacy The University of Arizona Cancer Center RENAL
More informationRenal Cell Carcinoma
Renal Cell Carcinoma Sequencing in renal cancer: two options for the same problem (TKImTOR) Viktor Grünwald Clinic for Hematology, Hemostasis, Oncology and Stemcelltransplantation Prof. Viktor Grünwald
More informationCase(s): How to Deal with Mixed Response Giuseppe Procopio
Case(s): How to Deal with Mixed Response Giuseppe Procopio Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Disclosures Advisory: Astellas, Bayer, GSK Consultant: Pfizer, Novartis Background Mixed
More informationThe plan. Overview of clinical trials Current clinical trials in renal cancer Future treatment of renal cancer
Relevant disclosure Bayer - consultancy GSK research funding, consultancy, speaker honoraria Novartis research funding Pfizer research funding, consultancy Roche / Genentech research funding, consultancy
More informationNivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial
Nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial H. Hammers, E.R. Plimack, J.R. Infante, M.S. Ernstoff, B. Rini, D.F. McDermott, A. Razak,
More informationMetastatic renal cancer (mrcc): Evidence-based treatment
Metastatic renal cancer (mrcc): Evidence-based treatment José M. Ruiz Morales, M.D. Hospital Médica Sur April 18th, 2018 4th ESO-ESMO Latin American Masterclass in Clinical Oncology Disclosures Consulting:
More informationSequential Therapy in Renal Cell Carcinoma*
Sequential Therapy in Renal Cell Carcinoma* Bernard Escudier, MD, Marine Gross Goupil, MD, Christophe Massard, MD, and Karim Fizazi, MD, PhD Because of the recent approval of several drugs for the treatment
More informationCurrent experience in immunotherapy for metastatic renal cell carcinoma
Current experience in immunotherapy for metastatic renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute FOIU, Tel Aviv, 3 July 2018 Financial and Other Disclosures Off-label use of drugs,
More informationRationale for VEGFR-targeted Therapy in RCC
Rationale for VEGFR-targeted Therapy in RCC EIKCS, Budapest, May 2013 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial Management Group Honoraria Astra Zeneca + + + Astellas
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationIntegrating novel therapy in advanced renal cell carcinoma
Integrating novel therapy in advanced renal cell carcinoma Tian Zhang, MD Assistant Professor of Medicine GU Oncology Duke Cancer Institute March 11, 2017 Disclosures Research Funding Janssen Pfizer Consultant
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More informationNEXT GENERATION DRUGS IN KIDNEY CANCER. Dr Aine O Reilly Karolinska Institutet Stockholm, Sweden
NEXT GENERATION DRUGS IN KIDNEY CANCER Dr Aine O Reilly Karolinska Institutet Stockholm, Sweden KIDNEY CANCER SUBTYPES Papillary Type 1 and 2 Medullary Collecting duct Chromophobe Translocation Clear cell
More informationADVISORY COMMITTEE BRIEFING MATERIALS: AVAILABLE FOR PUBLIC RELEASE
Tivozanib Hydrochloride in Advanced Renal Cell Carcinoma ADVISORY COMMITTEE BRIEFING MATERIALS: AVAILABLE FOR PUBLIC RELEASE AVEO PHARMACEUTICALS, INC. 75 Sidney Street Cambridge, MA 02139 Tel: (617) 299-5000
More informationTargeted and immunotherapy in RCC
Targeted and immunotherapy in RCC Treatment options Surgery (radical VS partial nephrectomy) Thermal ablation therapy Surveillance Immunotherapy Molecular targeted therapy Molecular targeted therapy Targeted
More informationCheckpointinhibitoren in der Uro-Onkologie. Carsten Grüllich
Checkpointinhibitoren in der Uro-Onkologie Carsten Grüllich 07.02.15 T-cell Aktivierung und Regulation T cell Costimulation Recognition MHC I Peptide b2m mrna Tumorantigen Tumor Pardoll Nature Rev Cancer
More informationINTEGRATION OF SURGERY AND SYSTEMIC THERAPY FOR ADVANCED RENAL CELL CARCINOMA IN THE TARGETED THERAPY ERA
INTEGRATION OF SURGERY AND SYSTEMIC THERAPY FOR ADVANCED RENAL CELL CARCINOMA IN THE TARGETED THERAPY ERA Dr. Michael J. Metcalfe PGY-4 Department of Urologic Sciences University of British Columbia October
More informationSurgery of Renal Cell Carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute
Surgery of Renal Cell Carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute 23 March 2012, Sao Paulo, Brazil Surgery of RCC Locally confined (small) renal tumours Locally advanced disease Metastatic
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationREAL WORLD PRACTICE: ADJUVANT THERAPY READY FOR PRIME TIME? PRO
REAL WORLD PRACTICE: ADJUVANT THERAPY READY FOR PRIME TIME? PRO Alain Ravaud, MD.PhD Bordeaux. France DISCLOSURES Consultant for: Pfizer, Novartis, GlaxoSmithKline, Roche, Bristol-Myers Squibb Institutional
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013
pan-canadian Oncology Drug Review Final Clinical Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationRenal Cell Carcinoma: Navigating a Maze of Choices
Renal Cell Carcinoma: Navigating a Maze of Choices Sumanta Kumar Pal, M.D. Associate Professor Department of Medical Oncology & Experimental Therapeutics Co-Director, Kidney Cancer Program City of Hope
More informationKidney Cancer Session
New Frontiers in Urologic Oncology September 12 th, 2015 Kidney Cancer Session Moderator: Philippe E. Spiess, M.D. Invited Faculty Members: Wade J. Sexton, MD Jeremiah J. Morrissey, PhD Agenda for Session
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationDose individualization of sunitinib in mrcc: Toxicity-adjusted dose or Therapeutic drug monitoring
Dose individualization of sunitinib in mrcc: Toxicity-adjusted dose or Therapeutic drug monitoring Alison Zhang 1, Peter Fox 1, Sally Coulter 4, Val Gebski 5, Bavanthi Balakrishnar 1, Christopher Liddle
More informationMedical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce
Medical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce Medical treatment of metastatic RCC in the elderly ( 65y): Members of the SIOG Taskforce
More informationTreatment of Renal Cell Carcinoma (RCC) in the Era of Targeted Agents
Conflict of Interest Treatment of Renal Cell Carcinoma (RCC) in the Era of Targeted Agents None Patrick Medina, PharmD, BCOP Associate Professor University of Oklahoma OKC, OK Learning Objectives Epidemiology
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationRiunione Monotematica A.I.S.F The future of liver diseases. HEPATIC NEOPLASMS The challenge for new drugs
Riunione Monotematica A.I.S.F. 2016 The future of liver diseases Milan 13 th -15 th October 2016 Centro Congressi Fondazione Cariplo HEPATIC NEOPLASMS The challenge for new drugs Massimo Iavarone Gastroenterology
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationAlternativas de Futuro en Cáncer Renal Enrique Grande
Alternativas de Futuro en Cáncer Renal Enrique Grande Hospital Ramón y Cajal de Madrid The ncreasingly Challenging Field of mrcc Sorafenib (US 2005, EU 2006) 3,4 Sunitinib (US & EU 2006) 3,4 Early 1940s:
More informationThe High-Dose Aldesleukin (IL-2) Select Trial in Patients with Metastatic RCC
The High-Dose Aldesleukin (IL-2) Select Trial in Patients with Metastatic RCC D McDermott, M Ghebremichael, S Signoretti, K Margolin, J Clark, J Sosman, J Dutcher, T Logan, R Figlin and M Atkins on behalf
More informationRenal Cell Cancer. Clinical case study 1 & 2. Petri Bono MD PhD Helsinki University Hospital Helsinki, Finland
Renal Cell Cancer Clinical case study 1 & 2 Petri Bono MD PhD Helsinki University Hospital Helsinki, Finland 1 Case study 1 - RCC and Lung Metastases Case study 1: Patient History Male, 63 years old Mild
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationWhy was HOPE 205 a Positive After Years of Negative Studies?
Why was HOPE 205 a Positive After Years of Negative Studies? Prof. Dr. med. Viktor Grünwald Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation Why do we pursue combinations?
More informationAxitinib in renal cell carcinoma: now what do we do?
Renal Cell Carcinoma Axitinib in renal cell carcinoma: now what do we do? Ian D. Davis Monash University Eastern Health Clinical School, Level 2, Box Hill, Victoria 3128, Australia Correspondence to: Ian
More informationAdjuvant therapy: Additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back
Adjuvant therapy: Additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back Neo adjuvant therapy: Treatment given as a first step to shrink a tumor
More informationThe Current Champion: Angiogenesis inhibitors
The Current Champion: Angiogenesis inhibitors Baek-Yeol RYOO University of Ulsan College of Medicine ASAN Medical Center Dept. of Oncology Seoul, Korea Survival probability Sorafenib: Overall Survival
More informationDISCLOSURE SLIDE. ARGOS: research funding, scientific advisory board
INTERIM ANALYSIS OF THE PHASE 3 ADAPT TRIAL EVALUATING ROCAPULDENCEL-T (AGS-003), AN INDIVIDUALIZED IMMUNOTHERAPY FOR THE TREATMENT OF NEWLY-DIAGNOSED PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationRenal Cell Cancer: Present and Future. Bernard Escudier, Gustave Roussy
Renal Cell Cancer: Present and Future Bernard Escudier, Gustave Roussy [HKIOF May 2017] Sponsored by Bristol- Myers Squibb OPDIVO Hong Kong prescribing information is available upon request Disclosures
More informationPrognostic Factors: Does It Really Matter if New Drugs for Targeted Therapy Will Be Used?
european urology supplements 8 (2009) 478 482 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prognostic Factors: Does It Really Matter if New Drugs for Targeted Therapy Will
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationManagement of High Risk Renal Cell Carcinoma
Management of High Risk Renal Cell Carcinoma Peter E. Clark, MD Professor and Chair, Department of Urology Carolinas HealthCare System Chair, Urologic Oncology Levine Cancer Institute October 14, 2017
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationA Phase II Study of Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma Patients
A Phase II Study of Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma Patients Viktor Grünwald, 1 David McDermott, 2 Michael Atkins, 3 Robert Motzer, 4
More informationAngiogenesis and tumor growth
Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133: 275-88 1 Angiogenesis
More informationCANCER UROLOGY VOL. 12. P. S. Borisov 1, M. I. Shkol nik 2, R. V. Orlova 3, P. A. Karlov 1 DOI: /
CANCER UROLOGY 3 6 VOL. The use of targeted therapies and selection of the optimal treatment sequence in heterogeneous population of patients with metastatic kidney cancer. Results of retrospective study
More informationIncorporating biologics in the management of older patients with metastatic colorectal cancer
Incorporating biologics in the management of older patients with metastatic colorectal cancer D Papamichael MB BS MD FRCP Cyprus Oncology Centre GSK Satellite Symposium SIOG APAC Singapore 12-13 July 2014
More informationAdvances in the Treatment of Renal Cell Carcinoma
Advances in the Treatment of Renal Cell Carcinoma Developed in collaboration Learning Objectives Upon completion, participants should be able to: Identify patients with metastatic renal cell carcinoma
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationInvented name/name: Avastin International non-proprietary name/common name: bevacizumab TYPE II VARIATION: EMEA/H/C/000582/II/0015
Invented name/name: Avastin International non-proprietary name/common name: bevacizumab TYPE II VARIATION: EMEA/H/C/000582/II/0015 Extension of indication to include: Avastin in combination with interferon
More informationTreatment Options in RCC: Past, Present and Future. Pr Stéphane Oudard, MD, PhD Georges Pompidou Hospital Paris, France
1 Treatment Options in RCC: Past, Present and Future Pr Stéphane Oudard, MD, PhD Georges Pompidou Hospital Paris, France 2 Renal Cell Carcinoma (RCC) 208,500 new cases of kidney cancer are diagnosed this
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
into consideration the concerns of the patient. Upon reconsideration of the perc Initial Recommendation,the Committee discussed feedback from the patient advocacy group reporting concerns that the definition
More informationAtezolizumab Adjuvant Study: Medical Oncologist Perspective. Sumanta K. Pal, MD City of Hope Comprehensive Cancer Center
Atezolizumab Adjuvant Study: Medical Oncologist Perspective Sumanta K. Pal, MD City of Hope Comprehensive Cancer Center Trial overview Key issues Outline Challenges with neoadjuvant therapy Placebo control
More informationMetastatic Renal Cell Cancer - Therapeutic Challanges 2011
Metastatic Renal Cell Cancer - Therapeutic Challanges 2011 Brian I. Rini, M.D. Department of Solid Tumor Oncology Cleveland Clinic Taussig Cancer Institute Glickman Urologic and Kidney Institute Cleveland,
More informationAdjusting the Crossover Effect in Overall Survival Analysis Using a Rank Preserving Structural Failure Time Model: The Case of Sunitinib GIST Trial
Adjusting the Crossover Effect in Overall Survival Analysis Using a Rank Preserving Structural Failure Time Model: The Case of Sunitinib GIST Trial Xin Huang 1 and Qiang (Casey) Xu 2 1 Pfizer Oncology
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More information